Search Within

David Hyman

  1. "American Association for Cancer Research"
Formats
  1. Journal Article (44)
  2. Meeting Abstract (38)
Groups
  1. Department of Medicine (82)
  2. Early Drug Development Service (82)
  3. Solid Tumor Oncology Division (82)
  4. GSK Faculty (55)
  5. Human Oncology and Pathogenesis Program (51)
  6. Department of Pathology and Laboratory Medicine (42)

More Groups

People
  1. David Solit (34)
  2. Michael Berger (28)
  3. Barry Taylor (22)
  4. Marc Ladanyi (21)
  5. Ahmet Zehir (20)
  6. Alison Schram (19)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (18)
  5. 2019 (24)
  6. 2018 (15)

More Years

Publications
  1. Cancer Research (32)
  2. Clinical Cancer Research (26)
  3. Cancer Discovery (18)
  4. Molecular Cancer Research (3)
  5. Molecular Cancer Therapeutics (2)
  6. Cancer Epidemiology Biomarkers and Prevention (1)
Publishers
  1. American Association for Cancer Research (82)

Results (82)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Natural history and characteristics of ERBB2-mutated hormone receptor-positive metastatic breast cancer: A multi-institutional retrospective case-control study from AACR Project GENIE
    Journal Article

    LeNoue-Newton, M. L.; Chen, S. C.; Stricker, T.; Hyman, D. M.; Blauvelt, N.; Bedard, P. L.; Meric-Bernstam, F.; Punglia, R. S.; Schrag, D.; Lepisto, E. M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • TRK XDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Journal Article

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arruabarrena-Aristorena, A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers
    Meeting Abstract

    Murciano-Goroff, Y. R.; Arbour, K. C.; Offin, M. D.; Tu, H. Y. Y.; Lebow, E. S.; Shaffer, T. S.; Bertucci, C.; Hosseini, S. A.; Garg, K.; Lim, L. P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; Coombs, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Community partnerships expand access to tumor molecular profiling
    Meeting Abstract

    Reynolds, T.; Jack, K.; Kemeny, M.; Bulone, L.; Gonsky, J.; Kampel, L. J.; Hyman, D.; Solit, D. B.; Conklin, C.; McMillan, S.; more...
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save